Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for naftifine, the scientific conclusions are as follows:

In view of available data on spontaneous reports including in some cases a close temporal relationship, and in view of a plausible mechanism of action, the PRAC considers a causal relationship between naftifine and "contact dermatitis" and "erythema" is at least a reasonable possibility. The PRAC concluded that the product information of products containing naftifine should be amended accordingly.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for naftifine the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing naftifine is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing naftifine are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

Section 4.8

Skin and subcutaneous tissue disorders

Not known (cannot be estimated from the available data): **contact dermatitis**, **erythema**

Package Leaflet

Section 4

Not known (frequency cannot be estimated from the available data): **contact dermatitis (skin rash or irritation at the application site), erythema (reddening of the skin)**

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	March 2021 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	09 May 2021
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	08 July 2021